Carboplatin versus etoposide/cisplatin for advanced metastatic seminoma

ISRCTN	ISRCTN27827390
DOI	https://doi.org/10.1186/ISRCTN27827390
Protocol serial number	TE12
Sponsor	Medical Research Council (MRC) (UK)
Funder	Medical Research Council (UK)

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Miss Sharon Naylor
Scientific

MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Scientific title
Study objectives	Compare the efficacy of carboplatin with a combination of etoposide and cisplatin in the treatment of advanced metastatic seminoma.
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cancer
Intervention	Arm 1 - 4 cycles of carboplatin. Arm 2 - 4 cycles of cisplatin/etoposide.
Intervention type	Drug
Phase	Not Specified
Drug / device / biological / vaccine name(s)	Carboplatin versus Etoposide / Cisplatin
Primary outcome measure(s)	Progression-free survival
Key secondary outcome measure(s)	Response, survival, toxicity.
Completion date	31/12/1995

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Target sample size at registration	112
Key inclusion criteria	Histologically verified testicular/extra-gonadal pure seminoma
Key exclusion criteria	Previous chemotherapy.
Date of first enrolment	01/08/1990
Date of final enrolment	31/12/1995

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/12/2000		Yes	No